A Japanese Multicenter, Open Label, Phase I Trial of c-Met Inhibitor MSC2156119J Given Orally as Monotherapy to Subjects With Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 10 Dec 2018
At a glance
- Drugs Tepotinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Merck KGaA
- 19 Apr 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 30 Jul 2014 Planned End Date changed from 1 Apr 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 30 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.